Agenus Reports Q4 and Year-End 2024 Results; Strategic Operational Improvements and Significant Cost Reductions Enhance Sustainability of Promising BOT/BAL ProgramBusiness Wire • 03/11/25
Agenus Reports Impact of Key Immuno-Oncology Data Presented at Leading Medical Conferences and Peer-Reviewed PublicationsBusiness Wire • 02/26/25
Agenus to Participate in B. Riley Securities Precision Oncology & Radiopharma Investor ConferenceBusiness Wire • 02/25/25
Agenus to Provide Corporate Update and Fourth Quarter & Full Year 2024 Financial ReportBusiness Wire • 02/25/25
Agenus Presents New Botensilimab/Balstilimab Data in Gastric Cancer at AACR IO Annual MeetingBusiness Wire • 02/24/25
CORRECTING and REPLACING Agenus' BOT/BAL Selected for Two Presentations at Upcoming AACR IO Annual MeetingBusiness Wire • 02/24/25
Agenus' BOT/BAL Selected for Two Presentations at Upcoming AACR IO Annual MeetingBusiness Wire • 02/12/25
Agenus Announces Publication in the Journal of Clinical Oncology Highlighting Data from Botensilimab Plus Balstilimab in Relapsed/Refractory Metastatic SarcomasBusiness Wire • 01/29/25
Agenus Presents Data at ASCO GI Demonstrating Impact of BOT/BAL in Colorectal Cancer Across Neoadjuvant and Advanced DiseaseBusiness Wire • 01/22/25
Agenus Announces Five Presentations at ASCO GI Highlighting BOT/BAL Activity Across Colorectal and Gastric CancersBusiness Wire • 12/18/24
Agenus Announces Strategic Realignment to Focus on Core Programs and Significantly Reduce CostsBusiness Wire • 12/05/24
Agenus Secures $22 Million Mortgage and Announces Strategic Operational RealignmentBusiness Wire • 11/27/24
Agenus (AGEN) Loses -41.56% in 4 Weeks, Here's Why a Trend Reversal May be Around the CornerZacks Investment Research • 11/19/24
Agenus (AGEN) Loses -41.13% in 4 Weeks, Here's Why a Trend Reversal May be Around the CornerZacks Investment Research • 11/18/24
Down -39.39% in 4 Weeks, Here's Why Agenus (AGEN) Looks Ripe for a TurnaroundZacks Investment Research • 11/15/24
Agenus Reports Third Quarter 2024 Financial Results and Strategic Advancements in BOT/BAL DevelopmentBusiness Wire • 11/12/24
November 5, 2024 Deadline: Contact Levi & Korsinsky to Join Class Action Suit Against - AGENAccesswire • 11/05/24